Pembrolizumab, Capecitabine, and Radiation Therapy in Treating Patients With Mismatch-Repair Deficient and Epstein-Barr Virus Positive Gastric Cancer

NCT03257163 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Epstein-Barr Virus Positive
Gastric Adenocarcinoma
Mismatch Repair Protein Deficiency
Stage IB Gastric Cancer AJCC v7
Stage II Gastric Cancer AJCC v7
Stage IIA Gastric Cancer AJCC v7
Stage IIB Gastric Cancer AJCC v7
Stage III Gastric Cancer AJCC v7
Stage IIIA Gastric Cancer AJCC v7
Stage IIIB Gastric Cancer AJCC v7
Stage IIIC Gastric Cancer AJCC v7

Interventions

DRUG: Capecitabine
OTHER: Laboratory Biomarker Analysis
BIOLOGICAL: Pembrolizumab
RADIATION: Radiation Therapy

Sponsor

Rutgers, The State University of New Jersey

Collaborators

[object Object]